Provista's intention of using Radient owned Onko-Sure seems pretty obvious. As usual, the devil is in the details. Look for our Friendly Skeptics to attempt to create uncertainty along the usual line "We can use their property as we please since the patents are expired."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.